

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 49D2302248	(X3) Date Survey Completed 01/15/2026
Name of Provider or Supplier Virginia Health Consultants	Street Address, City, State 1960 Gallows Road, #310, Vienna, VA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	An off-site CLIA proficiency testing (PT) desk review was conducted for Virginia Health Consultants on January 15, 2026 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. The laboratory was found to be out of compliance with the following CONDITION LEVEL DEFICIENCIES: D2016 - 42 CFR. 493.803 Condition: Successful Participation D6000 - 42 CFR. 493.1403 Condition: Laboratories performing moderate complexity testing- Laboratory Director.
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a review of the Certification and Survey Provider Enhanced Reporting</p>

(CASPER 0155) report, and the laboratory's proficiency testing (PT) records, the laboratory failed to successfully participate in the following: 1. The Routine Chemistry subspecialty and Prostate Specific Antigen analyte for three consecutive PT testing events. The laboratory had unsatisfactory Routine Chemistry and Prostatic Specific Antigen scores for the first, second and third events of calendar year 2025. Refer to D2096 and D2097. 2. The Endocrinology subspecialty and Testosterone analyte for two consecutive PT testing events. The laboratory had unsatisfactory Endocrinology and Testosterone scores for the second and third events of calendar year 2025. Refer to D2107 and D2108.

D2096

ROUTINE CHEMISTRY
CFR(s): 493.841(f)

(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:
Based on a proficiency testing (PT) desk review of the laboratory's Certification and Survey Provider Enhanced Reporting (CASPER)-0155 report and American Proficiency Institute (API) evaluation reports for 2025 (Events one, two and three), the laboratory failed to achieve satisfactory performance (80%) for the analyte Prostate Specific Antigen (PSA) for three of three events reviewed. The laboratory had unsatisfactory scores for PSA for 2025 Events one (1), two (2) and three (3) resulting in initial unsuccessful participation. The findings include: 1. Review of the CASPER-0155 report revealed the following unsatisfactory scores: 2025 Event 1: PSA = 20%, 2025 Event 2: PSA = 0%, 2025 Event 3: PSA = 0%. 2. A review of the laboratory's 2025 API PT scores for the analyte PSA confirmed the above findings resulting in initial unsuccessful participation for the analyte PSA.

D2097

ROUTINE CHEMISTRY
CFR(s): 493.841(g)

(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:
Based on a proficiency testing (PT) desk review of the laboratory's Certification and Survey Provider Enhanced Reporting (CASPER)-0155 report and American Proficiency Institute (API) evaluation reports for 2025 (Events one, two and three), the laboratory failed to achieve satisfactory performance (80%) for the subspecialty of Routine Chemistry for three of three events reviewed. The laboratory had unsatisfactory scores for Routine Chemistry for 2025 Events one (1), two (2) and three (3) resulting in initial unsuccessful participation. The findings include: 1. Review of the CASPER-0155 report revealed the following unsatisfactory scores: 2025 Event 1: Routine Chemistry = 20%, 2025 Event 2: Routine Chemistry = 0%, 2025 Event 3: Routine Chemistry = 0%. 2. A review of the laboratory's 2025 API PT scores for the subspecialty Routine Chemistry confirmed the above findings resulting in initial unsuccessful participation for the subspecialty Routine Chemistry.

<p>D2107</p>	<p>ENDOCRINOLOGY CFR(s): 493.843(f)</p> <p>(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on a proficiency testing (PT) desk review of the laboratory's Certification and Survey Provider Enhanced Reporting (CASPER)-0155 report and American Proficiency Institute (API) evaluation reports for 2025 (Events one, two and three), the laboratory failed to achieve satisfactory performance (80%) for the Testosterone analyte for two consecutive PT events reviewed. The laboratory had unsatisfactory scores for Testosterone for 2025 Events two (2) and three (3) resulting in initial unsuccessful participation. The findings include: 1. Review of the CASPER-0155 report revealed the following unsatisfactory scores: 2025 Event 1: Testosterone = 100%, 2025 Event 2: Testosterone = 0%, 2025 Event 3: Testosterone = 0%. 2. A review of the laboratory's 2025 API PT scores for the subspecialty Endocrinology confirmed the above findings resulting in an initial unsuccessful participation for the Testosterone analyte.</p>
<p>D2108</p>	<p>ENDOCRINOLOGY CFR(s): 493.843(g)</p> <p>(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on a proficiency testing (PT) desk review of the laboratory's Certification and Survey Provider Enhanced Reporting (CASPER)-0155 report and American Proficiency Institute (API) evaluation reports for 2025 (Events one, two and three), the laboratory failed to achieve satisfactory performance (80%) for the subspecialty of Endocrinology for two consecutive PT events. The laboratory had unsatisfactory scores for Endocrinology for 2025 Events two (2) and three (3) resulting in initial unsuccessful participation. The findings include: 1. Review of the CASPER-0155 report revealed the following unsatisfactory scores: 2025 Event 1: Endocrinology = 100%, 2025 Event 2: Endocrinology = 0%, 2025 Event 3: Endocrinology = 0%. 2. A review of the laboratory's 2025 API PT scores for the subspecialty Endocrinology confirmed the above findings resulting in initial unsuccessful participation for the Endocrinology subspecialty.</p>
<p>D6000</p>	<p>MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403</p> <p>The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.</p> <p>This CONDITION is not met as evidenced by:</p>

Based on a proficiency testing desk review of the Certification and Survey Provider Enhanced Reporting (CASPER) 155 report, and the 2025 American Proficiency Institute proficiency testing records, the laboratory director (LD) failed to ensure the overall quality of the laboratory services provided by failing to ensure successful participation in a Health and Human Services (HHS) approved Proficiency testing program. The laboratory had unsatisfactory scores for: 1. Routine Chemistry and Prostate Specific Antigen for the first, second and third events of calendar year 2025. Refer to D6016. 2. Endocrinology and Testosterone for the second and third events of calendar year 2025. Refer to D6016.

D6016

LABORATORY DIRECTOR RESPONSIBILITIES

CFR(s): 493.1407(e)(4)(i)

(e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part;

This STANDARD is not met as evidenced by:
Based on a review of the Certification and Survey Provider Enhanced Reporting (CASPER 0155) report, and the laboratory's 2025 proficiency testing (PT) records, the laboratory director (LD) failed to ensure the overall quality of the laboratory services provided. The LD failed to ensure successful participation in their Health and Human Services (HHS) approved PT program. The laboratory had unsatisfactory scores for: 1. Routine Chemistry and Prostate Specific Antigen for the first, second and third events of calendar year 2025. Refer to D2096 and D2097. 2. Endocrinology and Testosterone for the second and third events of calendar year 2025. Refer to D2107, and D2108.